Completed PHASE2 INTERVENTIONAL NCT00049179

S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML)

Sponsor: National Cancer Institute (NCI)

Conditions Leukemia

Interventions cytarabine gemtuzumab ozogamicin

Updated 7 times since 2017 Last updated: Mar 5, 2015 Started: Apr 30, 2003 Primary completion: Dec 31, 2005 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Leukemia and is currently completed. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2023 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
SWOG Cancer Research Network

Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Alton, United States , Anderson, United States , Asheboro, United States , Atlanta, United States , Austell, United States , Baton Rouge, United States , Beech Grove, United States , Bellingham, United States , Berkeley, United States and 82 more locations